PharmaFocus Today – Page 97 – media

Wayne State researchers investigate effects of fentanyl use during pregnancy

A new National Institutes of Health (NIH) grant will aid Wayne State University researchers in measuring the effects of fentanyl during pregnancy on maternal behaviors and offspring at birth through early development. This two-year, $423,500 grant, “Understanding the effects of gestational fentanyl exposure on external morphology, neonatal opioid withdrawal, and brain volume, morphology and neurochemistry of offspring,” is supported by the National Institute on Drug Abuse of the NIH. The principal investigators on this study are Shane Perrine, Ph.D., associate professor of psychiatry and behavioral neurosciences in Wayne State’s School of Medicine, and Susanne Brummelte, Ph.D., professor of psychology in Wayne State’s College of Liberal Arts and Sciences. “Our labs have collaborated on prior studies and this project is a natural extension of our previous work. I was working on the study of illicit fentanyl use and Susie’s lab was looking at the effects of opioids, including morphine and buprenorphine, ...
- Source: drugdu
- 160
- June 6, 2025
The second new drug application for the combination of Xindilimumab and Fruquintinib has been accepted by the National Medical Products Administration

On June 5th, Xinda Biotechnology and Hehuang Pharmaceutical jointly announced that the new drug application for the combination therapy of Xindilimumab and Fruquintinib for the treatment of locally advanced or metastatic renal cell carcinoma patients who have previously failed treatment with a tyrosine kinase inhibitor has been accepted by the National Medical Products Administration (NMPA) of China. It is reported that the combination therapy of xindilimab and furosemide obtained conditional approval from NMPA in December 2024 for the treatment of advanced mismatch repair intact (pMMR) endometrial cancer patients who have failed previous systemic anti-tumor therapy and are not suitable for radical surgery or radiotherapy.
- Source: drugdu
- 236
- June 6, 2025
BCHT’s recombinant shingles vaccine clinical trial application approved

On the evening of June 4, BCHT, the company announced that it had received the “Notice of Approval for Drug Clinical Trial” for the recombinant herpes zoster vaccine (CHO cells) issued by the National Medical Products Administration, and the conclusion was that it agreed to conduct clinical trials for the prevention of herpes zoster. Herpes zoster is an acute infectious skin disease caused by the reactivation of the varicella-zoster virus (VZV) lurking in the body. The recombinant herpes zoster vaccine (CHO cells) approved for clinical use by Biotech is for adults aged 40 and above. After vaccination, it can stimulate the body to produce immunity against the varicella-zoster virus and is used to prevent herpes zoster. According to reports, the recombinant shingles vaccine (CHO cells) developed by the company is based on varicella-zoster virus glycoprotein E (gE protein) and is combined with the company’s independently developed innovative BK-02 adjuvant system. ...
- Source: drugdu
- 219
- June 6, 2025
Nine-valent HPV vaccine approved for marketing

On the evening of June 4, Wantai BioThe company announced that the nine-valent human papillomavirus (HPV) vaccine (Escherichia coli) (trade name: Xinkening 9) jointly developed by the company’s wholly-owned subsidiary Xiamen Wantai Canghai Biotechnology Co., Ltd. (“Wantai Vaccine”) and Xiamen University has been approved for marketing by the National Medical Products Administration. Previously, there was only one nine-valent HPV vaccine on the market worldwide, which was developed by MerckGardasil® 9. Wantai Vaccine, located in Xiamen Biomedicine Port, has worked closely with the National Infectious Disease Diagnostic Reagent and Vaccine Engineering Technology Research Center (NIDVD) of Xiamen University to build a mature industry-university-research model. The two parties have developed and launched a number of innovative vaccines, from hepatitis E vaccine, bivalent HPV vaccine, to the current nine-valent HPV vaccine (Xinkening 9). The launch of Xinkening 9 is the result of 18 years of collaborative innovation in “industry-university-research” between the two parties. ...
- Source: drugdu
- 267
- June 6, 2025
Breakthrough in Alzheimer’s disease diagnosis and treatment

Alzheimer’s disease (AD) is a disease that scares countless families. It has an insidious onset, continues to progress, and is irreversible. Brain lesions have already occurred quietly 15 to 20 years before obvious symptoms appear. Moving the diagnosis and intervention window forward is a key measure to reduce the incidence of AD. In decades of exploration, existing drugs have always been trapped in the cage of “delaying symptoms”. Now, with the maturity of diagnostic technology and the emergence of a new generation of drugs targeting beta-amyloid protein (Aβ), the academic community sees hope of “pressing the pause button on the disease”. In 2021, Aducanumab received accelerated approval from the FDA, becoming the first new drug approved by the FDA for AD, for the treatment of AD-related mild cognitive impairment (MCI) and mild AD. In 2023, the FDA approved Lecanemab for the treatment of early AD with mild cognitive impairment or ...
- Source: drugdu
- 149
- June 6, 2025
After Apixaban! Who will be the next anticoagulant king?

Among the bright stars of antithrombotic drugs, there are two dazzling stars that must be mentioned. One is aspirin, which is known as the “world’s best-selling drug”. The annual global consumption is still over 100 billion tablets, which can circle the earth 25 times if they are lined up; the other is apixaban, which has continuously broken through sales since its launch and firmly sits at the top of the small molecule drug sales list. As a key drug category in the field of cardiovascular disease treatment, antithrombotic drugs firmly occupy the top position both in the global drug sales rankings and in the actual needs of clinical treatment. They are an indispensable “weapon” for the treatment of cardiovascular diseases. Nowadays, as the global population aging trend becomes more and more obvious, the number of patients with cardiovascular diseases continues to rise. At the same time, the steady improvement of ...
- Source: drugdu
- 263
- June 6, 2025
Gloria Pharmaceuticals and Eisai China Pharmaceuticals Signed a Marketing Service Agreement for Methylcobalamin Injection

On the evening of June 3, Gloria Pharmaceutical(002437) issued an announcement stating that the company’s wholly-owned subsidiary Tianjin Gloria Boda Technology Co., Ltd. (hereinafter referred to as “Tianjin Boda”) and Eisai (China) Pharmaceuticals Co., Ltd. (hereinafter referred to as “Eisai China Pharmaceuticals”) signed a “Marketing Service Agreement” for “Methylcobalamin Injection” (trade name: Mecobalamin). The agreement stipulates that Eisai China Pharmaceuticals authorizes Tianjin Boda to exclusively promote methylcobalamin injection in mainland China (excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan), and the authorization period is from June 1 to the expiration date of the agreement. Tianjin Boda is responsible for providing marketing services and other related services for the product in the above-mentioned regions. Gloria Pharmaceutical said that Tianjin Boda’s promotion of methylcobalamin injection will further enrich the company’s product pipeline and is expected to increase the company’s operating income and profits; in addition, it ...
- Source: drugdu
- 206
- June 4, 2025
Iopromide Injection Obtains Drug Registration Certificate

Starry Pharmaceutical announced on the evening of June 4 that its wholly-owned subsidiary Shanghai Sital recently received the “Drug Registration Certificate” for iopromide injection approved and issued by the National Drug Administration. This drug is indicated for use in diagnostic medication. It is used in blood vessels and body cavities. Computer X-ray tomography (CT) enhancement, arterial angiography and venography, arterial/venous digital subtraction angiography (DSA), especially suitable for cardiovascular angiography, intravenous urography, endoscopic retrograde pancreatocholangiopancreatography (ERCP), arthrography and other body cavity examinations, and cannot be used in the sheath. https://finance.eastmoney.com/a/202506043421771579.html
- Source: drugdu
- 158
- June 4, 2025
A new nuclear medicine company plans to go public in Hong Kong

In May, the Hong Kong-listed innovative drug sector was extremely lively. Rongchang Biopharma raised nearly 800 million yuan through allotment financing, Hengrui Medicine and Paige Biopharma were listed one after another, and Xiantong Pharmaceutical also submitted an application for listing. Xiantong Pharmaceutical is a new generation leading enterprise in the field of nuclear medicine. Its prospectus shows that its pre-IPO valuation has reached 5.188 billion yuan, and its cumulative financing has exceeded 2.9 billion yuan. With this IPO, Xiantong Pharmaceutical is expected to broaden its financing channels and accelerate the research and development and commercialization of its nuclear medicine products, which also marks a key step in the capitalization process of China’s nuclear medicine industry. Four core pipelines In the past two years, Xiantong Pharmaceutical’s operating income was RMB 10.232 million and RMB 44.064 million respectively, and the corresponding net losses were RMB 309 million and RMB 156 million respectively. ...
- Source: drugdu
- 402
- June 4, 2025
Hengrui is about to acquire the “first domestic

Chinese pharmaceutical companies represented by Hengrui Medicine and Ipomoea australis are actively planning the clinical development of URAT1 inhibitors. With the acceleration of the research process, a new generation of highly effective and low-toxic gout treatment drugs is expected to be quickly launched on the market, promoting innovation in the field of gout treatment. Significant clinical need Hyperuricemia is a metabolic syndrome caused by purine metabolism disorder. Its clinical diagnosis requires that the blood uric acid level of an adult exceeds 420μmol/L (7mg/dl) twice on different days. Gout is a crystal-related arthropathy. As a common metabolic rheumatic disease, its pathological basis is hyperuricemia – abnormal purine metabolism or reduced uric acid excretion causes increased blood uric acid, which in turn leads to the deposition of monosodium urate crystals. The current treatment of chronic hyperuricemia and gout mainly revolves around two core mechanisms: inhibiting uric acid synthesis and promoting uric acid ...
- Source: drugdu
- 181
- June 4, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.